Category Archives: Prescription Drug Abuse

Survey on Opioids in the Workplace Shows Impact on Employers

The results of a survey conducted by The Hartford, a leading property and casualty insurance company, have found the current opioid epidemic is having a “tangible and growing impact” on employers across the US. The survey also found that a majority of Human Resources (HR) professionals and workers feel they don’t have the knowledge or resources necessary to deal with addiction.

Companies of All Sizes Participated in Opioid Survey

Two thousand workers and 500 HR leaders participated in the national survey, which collected responses from companies of all sizes.

• Two-thirds of HR professionals (67 percent) said their company is being impacted by opioid use today, or will be in the future.
• Just under two-thirds of the HR professionals (65 percent) revealed that opioid addiction is impacting their company financially.

Employees, HR Staff Feel Unprepared for Substance Use Problems

The Hartford survey is an opportunity for employers to provide addiction education materials to workers, as well as develop and implement consistent policies and procedures regarding drug misuse.

• Many employees (76 percent), as well as HR professionals (64 percent), don’t feel they are well trained when it comes to helping co-workers who have an opioid addiction issue.
• When asked if they could spot the signs of an opioid addiction, 24 percent of HR professionals and 18 percent of employees felt extremely or very confident they could.
• Nineteen percent of HR professionals and employees feel they are extremely or very knowledgeable about how to reduce the risk of opioid addiction.

Survey Methodology

The Opioids in the Workplace survey was conducted with an online research panel on August 9-15, 2018. A representative sample of 2,500 US adults from across the nation was divided into two groups. Two thousand full and part-time workers and 500 participants with an HR role answered questions.

The margin of error for the first group is +/-2.2 percent at the 95 percent confidence level. For the second group, the margin of error is +/-4.4 percent at the 95 percent confidence level.

President Signs Bill to Curb Opioid Crisis

After declaring the US in the midst of a public health emergency in 2017 due to the opioid crisis, The President signed a bill into law that experts believe will help to curb the opioid crisis. The new legislation is called the SUPPORT for Patients and Communities Act.

More Funding for Addiction Treatment

The new law provides funding to federal agencies and states so that they can provide increased access to addiction treatment. It also puts measures in place to help alleviate the crisis, such as:

• Preventing overprescribing
• Training law enforcement agencies to intercept drug shipments at US borders

The bill signing was the culmination of a 12-month effort by the legislative and executive branch to react to the opioid crisis. While lawmakers said the bill was a step in the right direction, although many of them said it didn’t go far enough to deal with the epidemic. Rep. Frank Pallone of New Jersey cautioned of ramifications of talk of reducing access to publicly-funded treatment programs.

Congress and the White House entered into discussions for making a plan for confronting the epidemic in October 2017. This was before several congressional hearings by the House and the Senate on the same subject.

Public health experts have spoken out in favor of the bill, since it increases access to treatment. They say this is a critical step to controlling the epidemic. One of the measures in the legislation removes an old measure that didn’t allow clients with substance abuse issues get treatment in mental health facilities with more than 16 beds under Medicaid.

Private Companies on Board with New Initiatives

The White House has also pointed to new initiatives from private companies:

• Amazon has programmed its Alexa voice service to answer consumers’ questions about opioids and addiction.
• Blue Cross Blue Shield, the major insurance provider, will establish a national toll-free phone number to help US residents locate drug and alcohol treatment centers.
• Biopharmaceutical company Emergent BioSolutions will offer free Narcan nasal sprayers at over 16,500 public libraries and 2,700 YMCAs. Narcan, when administered to someone experiencing an opioid overdose, can help reverse the condition.

Treatment Still the Main Focus

What this new law and other efforts do is to help continue to focus on the need for treatment at all levels. This current drug crisis won’t subside until there are enough people seeking and receiving quality treatment for their substance use disorders. Desert Cove Recovery is proud to be a leader in rehabilitation for people both in Arizona and from all over the country.

Report on Substance Use: Alcohol Holds No. 1 Spot

Reports about the opioid crisis and drugs fentanyl, carfentanil and heroin have dominated recent headlines. During the years 200-2016, the number of lives lost to opioids has more than quadrupled. Though opioids have taken up a lot of our collective attention during the first part of the twenty-first century, it would be a mistake to ignore another addictive substances that have had a negative impact on people’s lives: alcohol.

A new report released from the California Health Care Foundation looked at substance use disorders in California. It examined the impact of alcohol, opioid and other substance use over time. Although this particular report was specific to California, the figures are a fair representation for situations in Arizona and nationwide as well.

Key Findings from Substance Abuse Report

The report, entitled “Substance Use in California: A Look at Addiction and Treatment,” has several key findings, including:

• Alcohol use disorder was the most common type of substance use disorder among California residents. Approximately six percent of Californians met the criteria for alcohol dependence. Three percent of state residents met the criteria for dependence on illicit drugs.

• Experimenting with drugs and alcohol is likely to start during the adolescent years. By the time they reach Grade 11, over half of students in California have tried alcohol and close to 40 percent have tried marijuana.

• Young adults (aged 18-25) were most likely to develop substance use disorders, with the likelihood close to twice the state average.

• The number of Emergency Department visits related to heroin in California has tripled during the years between 2006-2017.

• Alcohol was responsible for more nonfatal Emergency Department visits in California than all other drug diagnoses combined.

Substance Abuse Disorders Treatable

Substance use disorders, including alcohol use disorder, can be treated and managed. Like other chronic illnesses, the risk of relapse is a real and ongoing one. Behavioral therapy helps people with substance use disorders change unhealthy coping mechanisms for new ways of dealing with destructive behaviors. Medications can be used to control cravings for opioids and alcohol and reduce the physical reward a user experiences when they are ingested.

Naltrexone is among the most common medications, which is used in many different forms. Vivitrol is an monthly injectable version of naltrexone that is often used to help fight cravings.

Number of Pregnant Opioid Addicts Surged Over Last 15 Years

The results from a new report released from the Centers for Disease Control and Prevention (CDC) published in the CDC’s Morbidity and Mortality Weekly Report shed light on the continued effects of the opioid epidemic on a specific portion of the population: pregnant women. The researchers found that the number of women living with opioid use disorder at the time they went into labor and delivered their babies “more than quadrupled” during the 15-year period between 1999-2014.

Opioid Addiction Leads to Other Health Issues

Opioid addiction is responsible for a number of health problems. It can take a toll on a user’s physical and mental health, as well as her personal relationships. According to statistics collected by the CDC, opioids (which include prescription pain medications and illicit drugs such as heroin) were responsible for taking the lives of more than 42,000 people in 2016, a record level for fatalities.

Opioid use at addiction levels during pregnancy has been linked to several negative health consequences for mothers and babies. The drug use can lead to preterm birth, stillbirth and neonatal abstinence syndrome (NAS), a term describing a group of conditions caused when a fetus goes through withdrawal from certain drugs before birth.

National Database Analyzed

Researchers analyzed a national database collected on women from 28 states and discovered the rate of opioid use disorder jumped from 1.5/1000 delivery hospitalizations in 1999 to 6.5/1000 delivery hospitalizations in 2014. The rate increased by 0.39 cases per 1,000 during each year of the study.

Some geographical differences were noted during the study. The average annual increases were highest in West Virginia, Vermont, New Mexico and Maine. They were lowest in Hawaii and California.

Wanda Barfield, MD, Rear Admiral, US Public Health Service (USPHS), and the Director of the Division of Reproductive Health, explained that even in states with the smallest increases year over year, more pregnant women with opioid use disorder are being seen in labor and delivery.

Strategies for Dealing with Opioid Addiction in Pregnancy

The report included strategies for states to take on the issue of opioid addiction in pregnancy.

• Ensure opioid prescribing is in line with the CDC’s current guidelines
• Intensify prescription drug monitoring programs.
• Institute a policy of substance use screening at the first prenatal visit.
• Make certain that pregnant women with opioid use disorder have access to MAT (medication assisted therapy) and other addiction treatment services.
• Provide mothers with opioid use disorder with postpartum care that includes substance abuse treatment, mental health treatment, relapse prevention and family planning services.

Xanax Abuse Rates Rising

With all eyes on the opioid problem in America, many people are missing the fact that millions of people are also abusing other prescriptions, such as Xanax. These anti-anxiety drugs have a very high potential for abuse and addiction and there is evidence that it is becoming even more prevalent.

Xanax Seen as Safer than Other Drugs

Addiction specialists are expecting a continued increase in the number of teens and young adults addicted to Xanax and other sedatives belonging to a class of anti-anxiety drugs called benzodiazepines (“benzos”). A number of young people feel that Xanax is safer and more readily available than other drugs, but it is certainly just as dangerous. The drug is abused by itself and also commonly taken with other substances, such as painkillers or alcohol.

Like most other substances, people can develop a tolerance over time, requiring more of it to achieve the same effect. This can lead people who have legitimate prescriptions for the drug to eventually become dependent and sometimes even farther down the path toward addiction.

Often, teens are finding the pills in their parents’ or grandparents’ medicine cabinets, not realizing they can be just as dangerous as opioids or illicit drugs. The risk to health and life increases when Xanax is taken with other drugs and/or alcohol.

Risk of Addiction Higher with Younger Start

When Xanax use starts early in life, the risk of addiction increases. A recent US Surgeon General’s report on drugs and indicated that close to 70 percent of young people who experiment with an illicit drug before the age of 13 will become addicted within the next seven years. Waiting to try illicit drugs until after the age of 17 lowers the risk of addiction to 27 percent.

Addiction professionals are seeing a significant increase in the number of teens and young adults who are addicted to Xanax. Many of them are taking high doses of the drug on a daily basis, sometimes in combination with opioids and alcohol.

Sharon Levy, the director of adolescent addiction treatment at Boston Children’s Hospital, explained that hospitals see trends first. She stated that benzo use among adolescents has “skyrocketed” and that more young people are being admitted to hospitals for withdrawals due to the possibility of dangerous seizures. At the same time, fewer teens are seeking help for prescription opioid addiction.

Dentists Offer Option to Opioids for Pain Relief and Fighting Addiction

The opioid epidemic continues to rage through North America, and experts in East Tennessee are looking into the source of the problem. Many of them have determined that it can start with a trip to the dentist’s office.

Dr. Turner Emery, an oral surgeon on Knoxville, explained that doctors have been blamed for a lot of patients getting started on opioids. However, dentists also prescribe this class of medications to their patients, who are also put at risk for addiction.

Exparel Given at Time of Surgery

Dr. Emery is using a medication in his practice called Exparel to reduce risk of opioid addiction. It numbs the area around teeth that have been extracted for up to four days after oral surgery has been performed. When Exparel is used, a dental surgery patient may not need prescription pain medication at all.

The peak time for a dental patient to experience pain following wisdom teeth removal is on the second and third day following surgery, Dr. Emery explains. He has had a couple of patients who have had to take one or two doses of a narcotic, but most patients have been able to relieve their pain wth over the counter (OTC) medicines.

The medication is given by injection in each molar. Patients report that it reduces the need for narcotic pain medication and doesn’t make them feel drowsy during the first few days following their procedure.

First Exposure to Narcotics After Dental Surgery

A number of adolescents are first exposed to opioids following dental surgery. They may also be prescribed these strong pain medications following a sport injury. If a young person is prescribed more medicine than they need for the initial health condition, there is a concern that the opioid pain reliever may end up in someone else’s hands. The young person may continue taking the narcotic after the initial need for the strong pain medication has ended.

Medication Effective for Pain Relief

Exparel isn’t covered by all health insurance companies. The medication costs approximately $200.00, which can be a prohibitive factor for some patients and their families. Dr. Emery states that the medication works “really, really well” and that he has had good results with it.

New Research Examines at Link Between DNA and Opioid Addiction

Bentley University and Gravity Diagnostics have entered into a partnership to conduct research into whether a person’s DNA can predict susceptibility to opioid addiction. The results of this work could give doctors prescribing pain medication an indication of how likely a patient is to become addicted. It could also predict how well patients who already have an opioid addiction problem will respond to specific treatments.

From Prescription Opioid Use to Addiction

According to the National Institute on Drug Abuse (NIDA), between 21-29 percent of chronic pain patients don’t take their medications properly and more than 115 people lose their lives due to opioid overdose every day. The majority (80 percent) of heroin users began their slide toward this illicit drug by misusing prescription opioid pain relievers.

Researchers will examine individuals’ DNA to discover how susceptible this factor makes them to becoming opioid-dependent. For people who have already become addicted to opioids, the scientists will examine their DNA to determine whether they are likely to respond well to both opioid and non-opioid treatments.

The results of this work could have a significant influence on doctors’ decisions about whether to prescribe opioid to specific patients. When a physician does make the choice to prescribe an opioid pain medication, a patient’s DNA profile may influence how much of the medication he is prescribed. The research results can also influence how doctors treat patients with a history of addiction.

Partnership Includes Multiple Departments at Bentley

The partnership, which will last three years, will include faculty from several departments at Bentley: Natural and Applied Sciences, Sociology and Economics. A public health geneticist will also be on the team to provide assistance with research. Bentley students will enter and process data, and write computer scripts.

Gravity Diagnostics, a Northern Kentucky-based laboratory, is providing a $360,000.00 grant to finance the work. Bentley was selected as a research partner because, “[it is] doing successful research that is relevant to the world today.”

Data Analytics First Phase in Research

In the initial phase of the research, data analytics will be used to pinpoint the genetic features that are the best predictors for addiction and responses to treatment. Once they have been identified, these features and predictions will be tested by comparing them to DNA samples taken from active opioid addicts and those in recovery.

The goal is to discover why some people become addicted to substances quickly, while others can use the same drug and seem to be resistant to physical addiction for some time.

insurance coverage for addiction treatment

Increase Insurance Coverage for Addiction to Lower Risk of Opioid Deaths

Increase Insurance Coverage for Addiction to Lower Risk of Opioid Deaths

Patients who are living with an opioid addiction and want to get help shouldn’t be denied access to treatment by their health insurance providers. This statement was one of the new policy recommendations co-authored by Professor Claudio Nigg, from the Office of Public Health Studies, University of Hawaii at Mānoa.

Lack of Full Coverage for Addiction Treatment a Barrier

The most likely reason people who want, but don’t get, addiction treatment is that government and private insurance policies don’t cover the cost of getting help, according to a statement posted June 27, 2018, on the Society of Behavioral Medicine’s website.

Professor Nigg explained, “To fight the opioid addiction epidemic that is ravaging the US today, policymakers need to increase Medicaid funding for addiction treatment and declare the opioid epidemic to be a national emergency, and not just a public health emergency.”

On a typical day in the United States, 3,900 people start taking a prescription opioid medication for non-medical reasons. Dozens of people die each day from an opioid overdose. In 2016, 77 people died from an opioid overdose in Hawaii, according to the National Institute on Drug Abuse.

Medication-Based Treatment for Opioid Addiction

Research has shown that medication-based treatment (MAT) is one approach for clients living with opioid addiction. It includes two components.

First, clients take medication to decrease cravings for drugs (such as oxycodone, morphine and heroin). They also attend behavioral modification therapy (“talk therapy”), which helps them change their thinking and actions.

Funding for Counseling Needed Along with Medications

Professor Nigg points out that while many insurance programs will pay for the medication, getting funding for counseling is much more difficult. He points out that people need the talk therapy, not just the medications to be treated properly for their addiction.

Nigg is an expert in the behavioral health science field. He has studied theories of behavioral change throughout his career and has conducted research on the motivations for people to take part in healthier living strategies.

For more information on opioid addiction treatment, and to find out if you have insurance coverage for addiction treatment, give us a call today.

Generic Medications for Opioid Dependence

FDA Approves Two Generic Medications for Opioid Dependence Treatment

FDA Approves Two Generic Medications for Opioid Dependence Treatment

Mylan Technologies Inc. and Dr. Reddy’s Laboratories SA have received the go-ahead to market buprenorphine and naloxone sublingual film. These products will be made available to patients as generic versions of Suboxone, a medication used to treat opioid dependence.

Buprenorphine is used to reduce the severity of opioid withdrawal symptoms. Naloxone blocks their effects and reverses the same. The two medications can be used as part of an overall treatment program that includes counseling and prescription monitoring.

More Help Available for Opiate Addiction

Generic buprenorphine and naloxone sublingual film will be available in several dosage levels. These medications can only be prescribed by medical professionals certified by the Drug Addiction Treatment Act.

Dr. Scott Gottlieb, the FDA Commissioner, stated that the FDA is taking steps to “advance the development of improved treatments for opioid use disorder” and to ensure that these medications are available to patients who need them. He also said that includes “promoting the development of better drugs, and also facilitating market entry of generic versions of approved drugs to help ensure broader access.”

About Medication-Assisted Treatment

Medication-assisted Treatment (MAT) is a treatment option that uses FDA-approved medications (buprenorphine, methadone or naltrexone) along with counseling and other types of behavioral therapies, to treat opioid addiction. This form of treatment reduces the severity of withdrawal symptoms. The medications used for MAT don’t give participants the “high” or feeling of ecstasy normally associated with opioid abuse, although some of these medications can wind up being abused as well, so they alone are not a permanent solution.

At an appropriate therapeutic dose for a patient, buprenorphine is also supposed to reduce the pleasurable effects he would experience if he took other opioids. This effect would make continued use of opioids less attractive, therefore much less likely.

Patients who are receiving MAT for opioid use disorder benefit from this type of treatment in another way as well: they cut their risk of dying by 50 percent, according to the Substance Abuse and Mental Health Services Administration (SAMHSA).

opioid withdrawal symptoms

FDA Approves Non-Opioid Drug to Treat Opioid Withdrawal Symptoms

FDA Approves Non-Opioid Drug to Treat Opioid Withdrawal Symptoms

The US Food and Drug Administration (FDA) has approved Lucemyra (lofexidine hydrochloride) to treat opioid withdrawal symptoms in adults. This drug may lessen the severity of withdrawal symptoms; however, it may not prevent them.

Lucemyra is only approved for a treatment period of up to 14 days. The medication is not meant to be used as a treatment for opioid use disorder (OUD). It’s one part of a long-term treatment plan for patients with OUD.

Opioid Withdrawal Symptoms

When someone has been taking opioids over a period of time, he will develop a physical dependence on the drugs. This is to be expected, and doesn’t necessarily mean that a patient has become addicted to the medication. Withdrawal symptoms can occur in patients who have been using opioid pain medications as directed by their doctor and people with OUD.

These withdrawal symptoms include the following:

• Anxiety
• Cravings
• Diarrhea
• Difficulty sleeping
• Muscle aches
• Nausea
• Runny nose
• Sweating
• Vomiting

How Opioid Withdrawal is Typically Managed

For patients taking opioid pain medications as directed by a doctor, opioid withdrawal is typically managed by slowly tapering off the drug. This strategy is used to lessen the effects of withdrawal symptoms. Some patients are able to avoid experiencing withdrawal symptoms entirely.

In a patient with OUD, withdrawal is typically treated by substituting another opioid medication. In time, the dose is gradually reduced or the patient is switched to a maintenance therapy program. These medication-assisted therapy (MAT) treatments may use drugs like methadone, buprenorphine or naltrexone. Medications may be prescribed to treat specific symptoms, such as aches and pains or stomach upsets.

About Lucemyra

Lucemyra is taken orally and works by reducing the release of the brain chemical norepinephrine. Its actions are believed to play a role in several opioid withdrawal symptoms.